TEVA PHARMACEUTICAL INDUSTRIES LIMITED Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price

TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVJF) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $18.91 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-03.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-02-03

TEVA PHARMACEUTICAL INDUSTRIES LIMITED share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $18.91, a 23.03% increase from fiscal 2024.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $15.37.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $0.00.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $0.00.

Period end	Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month
2025-12-31	$18.91 10-K · filed 2026-02-03
2024-12-31	$15.37 10-K · filed 2026-02-03
2023-12-31	$0.00 10-K · filed 2026-02-03
2022-12-31	$0.00 10-K · filed 2025-02-05
2019-12-31	$16.99 10-K · filed 2022-02-09
2018-12-31	$17.01 10-K · filed 2021-02-10
2017-12-31	$17.44 10-K · filed 2020-02-21
2016-12-31	$44.24 10-K · filed 2019-02-19